Evaluating the inhibitory potential of Withania somnifera on platelet aggregation and inflammation enzymes: An in vitro and in silico study

Madhusudan, M. and Zameer, F. and Naidu, Akhilender and Nagendra Prasad, M. N. and Dhananjaya, B. L. and Raghavendra, H. (2016) Evaluating the inhibitory potential of Withania somnifera on platelet aggregation and inflammation enzymes: An in vitro and in silico study. Pharmaceutical Biology, 54 (9). pp. 1936-1941. ISSN 1744-5116

[img] Text (Full Text)
Evaluating the inhibitory potential of Withania.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy
Official URL: https://doi.org/10.3109/13880209.2015.1123729

Abstract

Context Withania somnifera (L.) Dunal is traditionally used for treating various ailments, but lacks scientific evaluation. Objective This study evaluates Withania somnifera (WS) for its effect on platelet activity and inflammatory enzymes. Materials and methods Aqueous and ethanolic (1:1) leaf extracts were subjected to in vitro indirect haemolytic activity using Naja naja venom, human platelet aggregation was quantified for lipid peroxidation using arachidonic acid (AA) as agonist and 5-lipoxygenase (5-LOX) levels were determined using standard spectrometric assays. Further, molecular docking was performed by the ligand fit method using molegro software package (Molegro ApS, Aarhus, Denmark). Results The study found that aqueous and ethanol extracts have very negligible effect (15%) with an IC50 value of 13.8 mg/mL on PLA2 from Naja naja venom. Further, extracts of WS also had very little effect (18%) with an IC50 value of 16.6 mg/mL on malondialdehyde (MDA) formation. However, a 65% inhibition of 5-LOX with an IC50 value of 0.92 mg/mL was observed in 1:1 ethanol extracts. The same was evident from SAR model with the active ingredient withaferin A binding predominantly on Phe 77, Tyr 98, Arg 99, Asp 164, Leu 168, Ser 382, Arg 395, Tyr 396 and Tyr 614 with an atomic contact energy value of −128.96 compared to standard phenidone (−103.61). Thus, the current study validates the application of WS for inflammatory diseases.

Item Type: Article
Subjects: B Life Science > Biotechnology
Divisions: Department of > Biotechnology
Depositing User: manjula User
Date Deposited: 19 Jun 2019 08:06
Last Modified: 19 Jun 2019 08:06
URI: http://eprints.uni-mysore.ac.in/id/eprint/3404

Actions (login required)

View Item View Item